BioSpace News Archive

Researchers at Ohio State University are using nanotechnology to boost the body’s ability to fight sepsis, a life-threatening condition that results from the body’s extreme reaction to infection.

The company said Fiasp is the “first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation.”

The study met one of its dual primary endpoints, progression-free survival, but missed the other endpoint, overall survival.

Although much of the recent attention to CRISPR gene editing has been negative, CRISPR still remains one of the great hopes for treating diseases.

How do you catch just one kind of fish in a sea of similar fish? That’s the question being answered by researchers at Nurix, except they aren’t catching fish – they are ‘catching’ proteins in your body.

Apellis Pharmaceuticals announced that its pegcetacoplan beat out Alexion Pharmaceuticals’ Soliris in its Phase III PEGASUS study in adults with paroxysmal nocturnal hemoglobinuria.

MiNA said the collaboration will combine its “expertise in the discovery and development of saRNA therapeutics” with AstraZeneca’s experience in “identifying and bringing breakthrough treatments to patients with metabolic diseases.”

A Chinese scientist living abroad who has been accused of accepting stolen intellectual property to benefit a pharma startup in China has been extradited to the United States.

Galecto, the leading developer of galectin modulators for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis and cancer, and PharmAkea, Inc., a privately held San Diego-based pharmaceutical company developing novel small molecules against protein targets involved in fibroproliferative disease, announced the two companies will merge.

TG4050 moves therapeutic vaccination into the digital age: combines Transgene’s expertise in viral vectors with NEC’s cutting-edge Artificial Intelligence (AI) capabilities